A huge thanks to all authors! @NiklasMattsson4

💡 Takeaway: • NfL is robust but not sufficient alone in low-prevalence settings. • Diagnostic and prognostic frameworks should move toward standardized multimodal models integrating fluid #biomarkers with established predictors. #ALS #MND

🚨Paper Out in @EANeurology! Systematic Review & Meta-analysis of ALS Fluid Biomarkers 🧵Key findings: • NfL leads for both diagnosis (AUC 0.81–0.92) & prognosis (HR 2.8–4.3) • CSF chitinases, p-tau/t-tau: moderate values • Marked heterogeneity 🔗 https://t.co/GlpyF0xejv

A huge thanks to all authors: @LECollij, @NiklasMattsson4, Shorena Janelidze, @RikOssenkoppele, and @OskarHansson9

🚨New publication in Alzheimer's & Dementia! In this perspective paper, we discuss whether Aβ blood biomarkers can replace the accepted reference standard, Aβ-PET, for assessing Aβ burden.🔗Full paper:

The study was led by Atul Kumar. Thank you to all co-authors: @DivyaBali06, @EStomrud, @SebastianPalmqv, @_JakeVogel_, @OskarHansson9, @NiklasMattsson4, and those not on X.

🚨New publication in Brain Communications! In this study, we show that microglial cells play a key role in Alzheimer's disease, particularly in regulating changes in soluble tau, based on cell-type-specific genetic evidence. 🔗Full paper:

@DAlcoleaR @sylv_villeneuve @pedrorosaneto @SuzanneESchind1 @RikOssenkoppele @OskarHansson9 with data from @amsterdamumc @BarcelonaBeta @MayoClinicNeuro @mcgillu @prevent_ad @WashUMedADRC @WisconsinADRC… and those not in X.

🙏Many thanks to all collaborators in this large study including 12 international cohorts: @DivyaBali06 @A_OrdunaDolado @JosephTherr @EStomrud @NiklasMattsson4 @EmmaCoomans @CharlotteTeuni1 @NesrineR95 @JuandoGispert @vincentDore2 @AzadehFeizpour

🎯The use of plasma p-tau217 will reduce resource demands and burdensome procedures accelerating the development and implementation of early AD therapeutics.

5⃣ In conclusion, our results support the clinical utility of plasma p-tau217 as stand-alone tool for identifying preclinical AD but adding confirmatory CSF/PET would further improve PPVs as needed in many clinical applications.

4⃣ Finally, in a subsample we tested whether mass-spectrometry (MS) based methods would improve the results compared to immunoassays (IA). MS showed significantly higher accuracy and sensitivity, but PPV remained comparable to that of IA.

3⃣ In a hypothetical trial aiming to recruit 100 amyloid-positive individuals, there was >40% reduction in number of PET/CSF tests in blood-based approaches, although the initial number of individuals needed were increased.

2⃣ Next, we investigated a 2-step approach in which 🩸p-tau217 positive individuals were confirmed with CSF or PET. With this approach, PPV increased to over 90% while maintaining sensitivity.

1⃣ In a sample of 2916 cognitively unimpaired individuals we found that plasma p-tau217🩸alone (single-step) was able to determine amyloid-β status with good accuracy and, most importantly, with a positive predictive value (PPV) of around 80%.

🚨Paper alert🚨 New publication in @JAMANeuro led by @gesalbla. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer's disease in cognitively unimpaired individuals. https://t.co/CLCtGxkV2P A 🧵...

The study was led by PhD students Pontus Tideman and @karlssonlinda1. Thank you also to all co-authors: @ErikRubenSmith @NiklasMattsson4 @EStomrud @SebastianPalmqv @OskarHansson9 and those not on X.

🚨New publication in Nature Medicine! In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting. Details: https://t.co/tSwVYOlzWS Full paper:

Big thanks to all co-authors and collaborators: @RikOssenkoppele @ErikRubenSmith @LECollij @aitchbi @jorittmo @karlssonlinda1 @DaniellevWe @JakeVogel @EStomrud @SebastianPalmqv @NiklasMattsson4 @NicolaSpotorno @OskarHansson9 + those not on X

7/🧵 These results suggest that hemispheric difference in Aβ deposition, rather than reduction in connectivity, is associated with asymmetric tau accumulation, highlighting regional vulnerability as a crucial factor in determining the distribution of AD pathology.